title: Effects of Oxandrolone on Cardiometabolic Health in Boys With Klinefelter Syndrome: A Randomized Controlled Trial.
abstract: Klinefelter syndrome (KS) is a common condition in males, resulting in androgen deficiency and cardiometabolic diseases. These interrelated conditions may be present in prepubertal boys with KS.
  
  
  
  To determine whether supplemental low-dose androgen has a beneficial effect on body composition in prepubertal boys with KS.
  
  
  
  We conducted a secondary analysis of a randomized, double-blind, placebo-controlled clinical trial in 93 boys with KS aged 4 to 12 years.
  
  
  
  Oral oxandrolone (Ox) 0.06 mg/kg/d or placebo for 2 years.
  
  
  
  The primary outcome was percent body fat standard deviation score (%BF SDS) at 2 years. Secondary outcomes included additional measures of cardiometabolic health and safety.
  
  
  
  The %BF SDS at 2 years was significantly lower in the treatment (0.29 ± 0.76 SDS) compared with placebo group (0.81 ± 0.72 SDS) after adjusting for age and baseline %BF SDS (95% confidence interval for the difference between means -0.86 to -0.19 SDS, P = 0.009). Ox resulted in lower triglycerides (P = 0.043), but also lower high-density lipoprotein (HDL) cholesterol (P < 0.001) and a more rapid advancement in bone age (P = 0.011).
  
  
  
  Ox has positive effects on measures of cardiometabolic health in prepubertal boys with KS; however, it does lower HDL cholesterol and advance bone age.
authors: Department of Pediatrics and.|Children's Hospital Colorado, Section of Pediatric Endocrinology, Aurora, CO 80045.
authors: Shanlee M
authors: SM
authors: Davis
authors: ACCORDS Program, University of Colorado School of Medicine, Aurora, CO 80045.
authors: Matthew G
authors: MG
authors: Cox-Martin
authors: Thomas Jefferson University, Department of Pediatrics, Philadelphia, PA 19107; and.|A.I. DuPont Hospital for Children, Wilmington, DE 19803.
authors: Martha Z
authors: MZ
authors: Bardsley
authors: Thomas Jefferson University, Department of Pediatrics, Philadelphia, PA 19107; and.|A.I. DuPont Hospital for Children, Wilmington, DE 19803.
authors: Karen
authors: K
authors: Kowal
authors: Department of Pediatrics and.|Children's Hospital Colorado, Section of Pediatric Endocrinology, Aurora, CO 80045.
authors: Philip S
authors: PS
authors: Zeitler
authors: Thomas Jefferson University, Department of Pediatrics, Philadelphia, PA 19107; and.|A.I. DuPont Hospital for Children, Wilmington, DE 19803.
authors: Judith L
authors: JL
authors: Ross
mesh_terms: D015415:Biomarkers / Q000032:analysis; D001823:Body Composition; D001827:Body Height / Q000187:drug effects*; D002318:Cardiovascular Diseases / Q000517:prevention & control*; D002648:Child; D004311:Double-Blind Method; D005500:Follow-Up Studies; D006801:Humans; D007713:Klinefelter Syndrome / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D008297:Male; D024821:Metabolic Syndrome / Q000517:prevention & control*; D010074:Oxandrolone / Q000627:therapeutic use*; D011379:Prognosis
chemical_list: D015415:Biomarkers; D010074:Oxandrolone